Meeting
2022 ASCO Annual Meeting
A clinical AI-driven multiplex immunofluorescence imaging pipeline to characterize tumor microenvironment heterogeneity.
Authors
Dmitry Zarubin
BostonGene, Waltham, MA
Dmitry Zarubin , Valeriy Belotskiy , Zhongmin Xiang , Arina Varlamova , Pavel Ovcharov , Ilia Galkin , Margarita Polyakova , Viktor Svekolkin , Grigory Perelman , Maria Bruttan , Jessica H. Brown , Ekaterina Postovalova , Aleksander Bagaev , Nathan Fowler
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Molecular Diagnostics and Imaging
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3020)
DOI
10.1200/JCO.2022.40.16_suppl.3020
Abstract #
3020
Poster Bd #
12
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Single cell transcriptomic profiling of appendiceal adenocarcinoma to identify rare tumor cells and a myeloid-enriched tumor microenvironment (TME).
First Author: Betul Beyza Gunes
Poster
2020 ASCO Virtual Scientific Program
First-in-human phase Ib study of ATRC-101, an engineered version of a patient-derived antibody targeting a tumor-restricted ribonucleoprotein complex.
First Author: Jonathan Eliot Benjamin
Poster
2018 ASCO Annual Meeting
Pelareorep to promote the expression of a IFN-gamma-related gene signature that predicts response to checkpoint blockade therapy.
First Author: Grey A Wilkinson
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Therapeutic checkpoint targets: Evaluation of co-expression profiles in individual tumor and immune cells in the tumor microenvironment of FFPE tissue.
First Author: Annelies Laeremans